NL192778C - Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt. - Google Patents

Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt. Download PDF

Info

Publication number
NL192778C
NL192778C NL8400488A NL8400488A NL192778C NL 192778 C NL192778 C NL 192778C NL 8400488 A NL8400488 A NL 8400488A NL 8400488 A NL8400488 A NL 8400488A NL 192778 C NL192778 C NL 192778C
Authority
NL
Netherlands
Prior art keywords
coenzyme
carnitine
combination
per
inhibits
Prior art date
Application number
NL8400488A
Other languages
English (en)
Dutch (nl)
Other versions
NL192778B (nl
NL8400488A (nl
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of NL8400488A publication Critical patent/NL8400488A/nl
Publication of NL192778B publication Critical patent/NL192778B/xx
Application granted granted Critical
Publication of NL192778C publication Critical patent/NL192778C/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NL8400488A 1983-02-16 1984-02-15 Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt. NL192778C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH85883 1983-02-16
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (3)

Publication Number Publication Date
NL8400488A NL8400488A (nl) 1984-09-17
NL192778B NL192778B (nl) 1997-10-01
NL192778C true NL192778C (nl) 1998-02-03

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8400488A NL192778C (nl) 1983-02-16 1984-02-15 Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt.

Country Status (11)

Country Link
US (1) US4599232A (ja)
JP (1) JPS59186914A (ja)
BE (1) BE898918A (ja)
CH (1) CH655005A5 (ja)
DE (1) DE3405581A1 (ja)
DK (1) DK165167C (ja)
FR (1) FR2543827B1 (ja)
GB (1) GB2137088B (ja)
IT (1) IT1170235B (ja)
NL (1) NL192778C (ja)
SE (1) SE457143B (ja)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (ja) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
US5981601A (en) * 1992-05-28 1999-11-09 Centre For Molecular Biology And Medicine Method for enhancing cellular bioenergy
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
AU739353B2 (en) * 1997-03-27 2001-10-11 Medifoods Inc. Nutritional composition for improvements in cell energetics
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
WO1999051252A1 (en) 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6335361B1 (en) 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
EP1250052A1 (en) * 2000-01-25 2002-10-23 Juvenon, Inc. Nutritional supplements for aged pets
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
AU2002309038B2 (en) * 2001-05-10 2007-05-17 Kaneka Corporation Compositions for transmucosal administration containing coenzyme Q as the active ingredient
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
EP1643863A2 (en) * 2003-07-10 2006-04-12 Carl A. Forest Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006012267A1 (en) * 2004-06-29 2006-02-02 Elixirin Corporation Dietary compositions for enhancing metabolism and reducing reactive oxygen species
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
TW200735863A (en) * 2006-01-13 2007-10-01 Elixirin Corp Dietary compositions for enhancing metabolism and reducing reactive oxygen species
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US7615324B2 (en) * 2007-03-14 2009-11-10 Fujifilm Corporation Photosensitive composition, and cured relief pattern production method and semiconductor device using the same
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
JP5343002B2 (ja) * 2007-06-22 2013-11-13 株式会社カネカ 生理活性物質含有組成物
TW200916090A (en) * 2007-06-22 2009-04-16 Kaneka Corp Composition comprising coenzyme Q10
JP5364580B2 (ja) * 2007-08-22 2013-12-11 株式会社カネカ 還元型補酵素ｑ１０の製造方法、ならびに、その安定化方法
US8778410B2 (en) * 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
BE898918A (nl) 1984-08-16
IT8323559A0 (it) 1983-10-31
GB8403668D0 (en) 1984-03-14
SE457143B (sv) 1988-12-05
JPS59186914A (ja) 1984-10-23
DK72284D0 (da) 1984-02-16
SE8400851D0 (sv) 1984-02-16
GB2137088A (en) 1984-10-03
DK165167B (da) 1992-10-19
NL192778B (nl) 1997-10-01
US4599232A (en) 1986-07-08
DE3405581A1 (de) 1984-10-18
SE8400851L (sv) 1984-08-17
GB2137088B (en) 1986-02-05
NL8400488A (nl) 1984-09-17
CH655005A5 (it) 1986-03-27
DE3405581C2 (ja) 1992-10-22
FR2543827A1 (fr) 1984-10-12
FR2543827B1 (fr) 1987-06-12
IT1170235B (it) 1987-06-03
DK72284A (da) 1984-08-17
JPH027572B2 (ja) 1990-02-19
DK165167C (da) 1993-03-01

Similar Documents

Publication Publication Date Title
NL192778C (nl) Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt.
Kamikawa et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris
Capuzzi et al. Niacin dosing: relationship to benefits and adverse effects
Hendrickson et al. Free fatty acid metabolism during myocardial ischemia and reperfusion
US4255449A (en) Method of treating abnormal lipoprote in ratios
Judah et al. Biochemical mechanisms of liver injury
Ferder et al. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse
Beatty et al. Interrelation of carbohydrate and palmitate metabolism in skeletal muscle
US5643951A (en) Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders
Davidoff Effects of guanidine derivatives on mitochondrial function: I. Phenethylbiguanide inhibition of respiration in mitochondria from guinea pig and rat tissues
Bahl et al. Carnitine transport in isolated adult rat heart myocytes and the effect of 7, 8-diOH chlorpromazine.
McCord et al. Mitochondrial injury by ischemia and reperfusion
Duran et al. Octanoic acidemia and octanoylcarnitine excretion with dicarboxylic aciduria due to defective oxidation of medium-chain fatty acids
Shug et al. Protective effects of propionyl-L-carnitine during ischemia and reperfusion
US4578400A (en) Therapeutic composition and method for treatment of cardiovascular diseases
Thayer Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver: a possible model for Reye's syndrome
US5102910A (en) Pharmaceutical preparation and method of treatment for liver dysfunction
Gerova et al. Efficiency of NO donors in substituting the impaired endogenous NO production: functional and morphological study
Silverman et al. Effect of carnitine on myocardial function and metabolism following global ischemia
DE60306410T2 (de) Verbesserung des alkoholstoffwechsels
Baum The cellular basis of Fanconi syndrome
Chiariello et al. Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion
MXPA02000912A (es) Uso de l-carnitina y sus derivados alcanoilo para la preparacion de un medicamento util para el tratamiento de pacientes que sufren nefropatias diabeticas o por insuficiencia metabolica.
Alexander et al. Lithium toxicology: effect of isotopic composition on lethality and behavior
Genovese et al. Myocardial hypertrophy in the rat correlation between two experimental models

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20040215